Company Filing History:
Years Active: 2018
Title: Maria Luisa Macheda: A Pioneer in RYK-Targeted Antibody Development
Introduction
Maria Luisa Macheda is an innovative inventor based in St. Albans, Australia. She has made significant contributions to the field of biomedicine with her pioneering work on antibodies against human RYK, a receptor involved in critical cellular signaling processes. Her research has the potential to impact therapies related to various diseases, including cancer.
Latest Patents
Maria Luisa Macheda holds a patent titled "Antibodies against human RYK and uses therefor." This invention focuses on isolated monoclonal antibodies and their antigen-binding fragments that specifically bind to the extracellular domain of human RYK, particularly targeting the WIF domain. The antibodies developed in this patent demonstrate the ability to modulate RYK-associated activities, which include the regulation of Wnt-induced signaling pathways. Notably, her antibodies inhibit the binding of Wnt5a and prevent Wnt-induced phosphorylation of Dishevelled 2 and/or Dishevelled 3 proteins, showcasing their therapeutic potential.
Career Highlights
Maria is associated with the Peter MacCallum Cancer Institute, a leading cancer research and treatment center. Her work in this esteemed institution underscores her commitment to advancing cancer research and finding innovative solutions for treatment. Throughout her career, she has remained dedicated to boosting the understanding of RYK signaling and its implications in various diseases.
Collaborations
Among her notable collaborators are Michael Maurice Halford and Steven Alan Stacker, prominent figures in the field who have contributed significantly to enhancing the scope and depth of her research. Through teamwork and shared expertise, they have collectively advanced the understanding and application of RYK-targeted therapies.
Conclusion
Maria Luisa Macheda stands out as a remarkable inventor contributing to the field of antibody development against human RYK. With a focus on modulating RYK-associated activities through her patent, she is paving the way for innovative treatments. Her collaborative efforts at the Peter MacCallum Cancer Institute reflect a dedication to advancing medical science and improving patient outcomes.